"We believe that our proposal presents a compelling value proposition for PharMerica stockholders. We disagree with PharMerica's regulatory analysis, and disagree that a $15 per share cash proposal, not conditioned on financing, is 'highly conditional and risky.' We urge PharMerica to sit down with us to engage in meaningful discussions.
"We remain firmly committed to pursuing this transaction and continue to be very confident in our ability to consummate a transaction expeditiously."
Goldman, Sachs & Co. is acting as financial advisor to Jpjzqbcm qmd Xoahl & IzBlvvs WFD ebk Hmojl, Muyxetv & Nrqlqxyvo JPQ vzy wnxghh lc itgos ssqsgtj.